Recurrent Oral Cavity Squamous Cell Carcinoma Clinical Trials

7 recruiting

Recurrent Oral Cavity Squamous Cell Carcinoma Trials at a Glance

10 actively recruiting trials for recurrent oral cavity squamous cell carcinoma are listed on ClinicalTrialsFinder across 6 cities. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Atlanta, Philadelphia, and Chicago. Lead sponsors running recurrent oral cavity squamous cell carcinoma studies include National Cancer Institute (NCI), Emory University, and M.D. Anderson Cancer Center.

Browse recurrent oral cavity squamous cell carcinoma trials by phase

Treatments under study

About Recurrent Oral Cavity Squamous Cell Carcinoma Clinical Trials

Looking for clinical trials for Recurrent Oral Cavity Squamous Cell Carcinoma? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Recurrent Oral Cavity Squamous Cell Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Recurrent Oral Cavity Squamous Cell Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 2

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Recurrent Head and Neck Squamous Cell CarcinomaLocally Recurrent Hypopharyngeal Squamous Cell Carcinoma+15 more
National Cancer Institute (NCI)180 enrolled40 locationsNCT07195734
Recruiting
Phase 2

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell CarcinomaRecurrent Oropharyngeal Squamous Cell CarcinomaRecurrent Hypopharyngeal Squamous Cell Carcinoma+2 more
National Cancer Institute (NCI)188 enrolled177 locationsNCT04671667
Recruiting
Phase 2

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Head and Neck Squamous Cell Carcinoma+22 more
National Cancer Institute (NCI)150 enrolled221 locationsNCT05136196
Recruiting
Phase 3

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Metastatic Head and Neck Squamous Cell CarcinomaStage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Recurrent Head and Neck Squamous Cell Carcinoma+18 more
National Cancer Institute (NCI)158 enrolled176 locationsNCT06589804
Recruiting
Not Applicable

Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation

Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaStage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8+30 more
Emory University118 enrolled1 locationNCT06662058
Recruiting
Phase 2

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaStage III Laryngeal Cancer AJCC v8+19 more
National Cancer Institute (NCI)44 enrolled5 locationsNCT06980038
Recruiting
Phase 1

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Metastatic Head and Neck Squamous Cell CarcinomaStage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Recurrent Head and Neck Squamous Cell Carcinoma+20 more
Emory University40 enrolled2 locationsNCT06868433
Recruiting
Phase 2

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaClinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8+19 more
Emory University28 enrolled2 locationsNCT06636734
Recruiting
Phase 1

Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer

Locally Recurrent Head and Neck Squamous Cell CarcinomaRecurrent Laryngeal Squamous Cell CarcinomaRecurrent Oral Cavity Squamous Cell Carcinoma+3 more
Ohio State University Comprehensive Cancer Center45 enrolled1 locationNCT04754321
Recruiting
Phase 2

Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).

Locally Recurrent Oral Cavity Squamous Cell Carcinoma
M.D. Anderson Cancer Center17 enrolled1 locationNCT06448026